Tezepelumab: A new pathway to asthma control

@inproceedings{Shaw2017TezepelumabAN,
  title={Tezepelumab: A new pathway to asthma control},
  author={Joanne Shaw},
  year={2017}
}
Our understanding of the complex mechanisms of inflammation, which result in the clinical entity we call ‘asthma’, has improved exponentially over the last few decades. This knowledge has resulted in the development of targeted biological therapy with several monoclonal antibodies, including those directed against IgE (omalizumab), interleukin-13 (tralokinumab), interleukin-5 (mepolizumab and reslizumab), and the alpha subunits of the interleukin-4 and interleukin-5 receptors (dupilumab and… CONTINUE READING